Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

I maintain a buy rating for ACCD as I expect growth reacceleration in FY25 which will drive valuation upwards. ACCD's management has raised revenue expectations for FY24 and reiterated long-term revenue targets. Potential risks include rising interest rates and the possibility of management missing profit outlook, which could lead to a lower stock price.

Accolade: Growth Reacceleration In FY25 Should Drive Valuation Upside

Accolade Inc. NASDAQ: ACCD is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people manage their health by finding the right care and providers.

Accolade: A Rising Personalized AI-Powered Healthcare Platform

The specialty healthcare solutions provider unveiled its latest set of quarterly results. These handily beat analyst estimates on both the top and bottom lines.

Why Accolade Stock Popped by Almost 7% Today

Accolade, Inc. (NASDAQ:ACCD ) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Health Officer Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Jeff Garrow - Stephens, Inc. Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Ryan MacDonald - Needham and Company Jonathan Yong - Credit Suisse Jailendra Singh - Truist Securities Sandy Draper - Guggenheim Stan Berenshteyn - Wells Fargo David Larsen - BTIG Robert Simmons - D.A. Davidson Operator Good day, and thank you for standing by, and welcome to Accolade First Quarter '24 Earnings Results Conference Call.

Accolade, Inc. (ACCD) Q1 2024 Earnings Call Transcript

SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2023.

Accolade Announces Results for Fiscal First Quarter 2024

SEATTLE, June 13, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal first quarter 2024 financial results on Thursday, June 29, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal First Quarter 2024 Financial Results

Accolade and Equip offer employers purpose-built integrations to address barriers to eating disorder treatment. SEATTLE , June 7, 2023 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with Personalized Healthcare, has partnered with Equip, a virtual evidence-based treatment program that helps patients recover from eating disorders at home.

Equip Partnership Adds Eating Disorder Support to Accolade's Trusted Partner Ecosystem

New health trends report explores causes of stress and offers solutions, including virtual care expansion and enhanced health equity. SEATTLE , June 5, 2023 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today findings of a new Savanta employer healthcare survey that shows nearly half of employees (49%) are overwhelmed by managing their own and their family members' healthcare and about two-thirds (65%) have delayed or avoided care as a result.

Report: Employees are Overwhelmed, Delaying Care at High Rates

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stifel 2023 Cross Sector Insight Conference in Boston on Tuesday, June 6, 2023 at 11:30 am ET. A webcast of the event will be available at ir.accolade.com and a replay will be available for 90 days.

Accolade To Present at Stifel 2023 Cross Sector Insight Conference

ACCD has experienced high demand, with revenue increasing by 5.6% in 4Q23 and a 33% increase in ARR bookings. During the analyst day, ACCD upgraded its FY25 margin target and expressed confidence in reaching $500 million in sales.

Accolade: FY25 And Long-Term Targets Inspire Confidence

Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accolade (ACCD) Upgraded to Buy: What Does It Mean for the Stock?

Bio-Rad Laboratories

Quest Diagnostics

Sangamo Therapeutics

Sotera Health

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)

Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript.

Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript

Accolade (ACCD) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.27 per share a year ago.

Accolade (ACCD) Reports Q4 Loss, Misses Revenue Estimates

SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 28, 2023.

Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2023

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will host an Analyst Day at the Wynn Las Vegas on May 8, 2023 and will provide a webcast of the event beginning at 1pm PT.

Accolade to Webcast Analyst Day on May 8, 2023

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal fourth quarter 2023 financial results on Thursday, April 27, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Fourth Quarter 2023 Financial Results

Seattle and Philadelphia area-based primary healthcare company Accolade is cutting its workforce and closing or reducing some facilities, according to a recent regulatory filing.

Healthcare company Accolade lays off workers and closes offices

Accolade and Lyra will offer employers purpose-built integrations that help address barriers to behavioral health care SEATTLE , March 6, 2023 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with Personalized Healthcare, has partnered with Lyra Health, a leading provider of global workforce mental health solutions. By adding Lyra to its Trusted Partner Ecosystem , Accolade is building on its commitment to offer best-in-class behavioral health solutions to its customers through both strategic partnerships and in-house capabilities.

Accolade Welcomes Lyra Health to Its Trusted Partner Ecosystem

Co-founder of Concur joins Board after serving as the Company's CIO Co-founder of Concur joins Board after serving as the Company's CIO

Michael Hilton Joins Accolade Board of Directors

The nonprofit health plan teams up with Accolade and TeleMed2U to connect members to virtual and in-person care through a new, virtual-first plan. OAKLAND, Calif.

Blue Shield of California Launches Virtual Blue Benefit Plan Incorporating Primary, Mental Health, and Specialty Care

Strong revenue growth and encouraging guidance pushed the stock up.

Why Shares of Accolade Soared This Week

Accolade, Inc. (NASDAQ:ACCD ) Q3 2023 Earnings Conference Call January 9, 2023 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair & Company Cindy Motz - Goldman Sachs Craig Hettenbach - Morgan Stanley Glen Santangelo - Jefferies Jonathan Yong - Credit Suisse William Hoover - Canaccord Genuity Jailendra Singh - Truist Ryan MacDonald - Needham Jessica Tassan - Piper Sandler. Stephanie Davis - SVB Securities Stanislav Berenshteyn - Wells Fargo Robert Simmons - D.A.

Accolade, Inc. (ACCD) Q3 2023 Earnings Call Transcript

Accolade (ACCD) delivered earnings and revenue surprises of 8.20% and 4.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates

SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2022.

News for Accolade Stock (ACCD)